ABBV250110C180000
- 0.01
- 0.000.00%
AbbVie Newsroom
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
AbbVie (ABBV) Receives a Buy From Morgan Stanley
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Johnson & Johnson (JNJ)
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $195
Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV)
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $212
Redburn Atlantic Adjusts Price Target on AbbVie to $216 From $214, Maintains Buy Rating
MoonLake Upgraded at Goldman Sachs on Promise of Hidradenitis Suppurativa Asset
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $208
Redburn Atlantic Adjusts Price Target on AbbVie to $214 From $216, Keeps Buy Rating
AbbVie's Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie Price Target Cut to $211.00/Share From $215.00 by Truist Securities
AbbVie Analyst Ratings
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $211
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191